Clinical Trials Browser

Phase 1/2 × defactinib × Other solid neoplasm × Clear all

NCT02758587 2018-03-19

Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

Phase 1/2 Unknown

GastrointestinalOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Pancreatic Neoplasms